OTSSP167MELK inhibitor CAS# 1431697-89-0 |
- OTSSP167
Catalog No.:BCC4314
CAS No.:1431697-89-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1431697-89-0 | SDF | Download SDF |
PubChem ID | 71543332 | Appearance | Powder |
Formula | C25H28Cl2N4O2 | M.Wt | 487.42 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | MELK inhibitor | ||
Solubility | Soluble to 0.5 mg/mL warmed (1.02 mM) in DMSO | ||
Chemical Name | 4-[7-acetyl-8-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1H-1,5-naphthyridin-2-ylidene]-2,6-dichlorocyclohexa-2,5-dien-1-one | ||
SMILES | CC(=O)C1=CN=C2C=CC(=C3C=C(C(=O)C(=C3)Cl)Cl)NC2=C1NC4CCC(CC4)CN(C)C | ||
Standard InChIKey | WZJUACDPTWDYSI-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C25H28Cl2N4O2/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3/h8-12,15,17,30H,4-7,13H2,1-3H3,(H,28,29) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | OTSSP167 is an inhibitor of maternal embryonic leucine zipper kinase (MELK) with IC50 value of 0.41nM . | |||||
Targets | MELK | |||||
IC50 | 0.41nM |
OTSSP167 Dilution Calculator
OTSSP167 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0516 mL | 10.2581 mL | 20.5162 mL | 41.0324 mL | 51.2905 mL |
5 mM | 0.4103 mL | 2.0516 mL | 4.1032 mL | 8.2065 mL | 10.2581 mL |
10 mM | 0.2052 mL | 1.0258 mL | 2.0516 mL | 4.1032 mL | 5.129 mL |
50 mM | 0.041 mL | 0.2052 mL | 0.4103 mL | 0.8206 mL | 1.0258 mL |
100 mM | 0.0205 mL | 0.1026 mL | 0.2052 mL | 0.4103 mL | 0.5129 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
OTSSP167 is an inhibitor of maternal embryonic leucine zipper kinase (MELK) with IC50 value of 0.41nM [1].
MELK is a member of the AMPK serine/threonine kinase family and is involved in the mammalian embryonic development. It plays roles in cancer cell growth and formation or maintenance of cancer stem cells. OTSSP167 is a small-molecule inhibitor and can inhibit MELK’s activity effectively and selectively. OTSSP167 inhibits cell proliferation of a variety of cancer cell lines including A549, T47D, DU4475 and 22Rv1. The IC50 values are 6.7nM, 4.3nM, 2.3nM and 6nM, respectively. In mice bearing MDA-MB-231 xenograft, administration of OTSSP167 inhibits 70% tumor growth at dose of 20 mg/kg. Besides that, OTSSP167 is also found to have effects on PSMA1 and DBNL which are the novel substrates of MELK. It inhibits the phosphorylation of PSMA1 and DBNL causes the subsequent suppression of mammosphere formation [1].
References:
[1] Chung S, Suzuki H, Miyamoto T, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget, 2012, 3(12): 1629.
- AT7867 dihydrochloride
Catalog No.:BCC1378
CAS No.:1431697-86-7
- AT7519 trifluoroacetate
Catalog No.:BCC1377
CAS No.:1431697-85-6
- gamma-secretase modulator 3
Catalog No.:BCC1585
CAS No.:1431697-84-5
- CAL-130 Hydrochloride
Catalog No.:BCC1441
CAS No.:1431697-78-7
- CAL-130
Catalog No.:BCC1440
CAS No.:1431697-74-3
- UNC1999
Catalog No.:BCC4552
CAS No.:1431612-23-5
- H-D-Ala-OMe.HCl
Catalog No.:BCC3199
CAS No.:14316-06-4
- BMX-IN-1
Catalog No.:BCC1434
CAS No.:1431525-23-3
- GSK-LSD1 2HCl
Catalog No.:BCC5647
CAS No.:1431368-48-7
- Neotuberostemonine
Catalog No.:BCN6239
CAS No.:143120-46-1
- BQ-3020
Catalog No.:BCC5728
CAS No.:143113-45-5
- Phytic acid sodium salt hydrate
Catalog No.:BCN1283
CAS No.:14306-25-3
- SB-408124 Hydrochloride
Catalog No.:BCC1929
CAS No.:1431697-90-3
- CCT241533 hydrochloride
Catalog No.:BCC1463
CAS No.:1431697-96-9
- KN-92 hydrochloride
Catalog No.:BCC1681
CAS No.:1431698-47-3
- (S)-Tedizolid
Catalog No.:BCC1294
CAS No.:1431699-67-0
- WEHI-539
Catalog No.:BCC2055
CAS No.:1431866-33-9
- K02288
Catalog No.:BCC5084
CAS No.:1431985-92-0
- 3'-O-Galloylmyricitrin
Catalog No.:BCN8268
CAS No.:143202-36-2
- WAY 267464 dihydrochloride
Catalog No.:BCC7813
CAS No.:1432043-31-6
- Nyasicol 1,2-acetonide
Catalog No.:BCN6879
CAS No.:1432057-64-1
- Catalponol methylthiomethyl ether
Catalog No.:BCC8905
CAS No.:1432057-74-3
- 10-Acetoxyscandine
Catalog No.:BCN7035
CAS No.:1432058-90-6
- 3-(3-Hydroxy-3-methylbutanyl)-2,4,6-trihydroxybenzophenone
Catalog No.:BCC8588
CAS No.:1432062-53-7
MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.[Pubmed:28214016]
Gynecol Oncol. 2017 Apr;145(1):159-166.
OBJECTIVE: Maternal embryonic leucine-zipper kinase (MELK) shows oncogenic properties in basal-like breast cancer, a cancer subtype sharing common molecular features with high-grade serous ovarian cancer. We examined the potential of MELK as a molecular and pharmacological target for treatment of epithelial ovarian cancer (EOC). METHODS/MATERIALS: Bioinformatic analysis was performed on nine OC transcriptomic data sets totaling 1241 patients. Effects of MELK depletion by shRNA or inhibition by OTSSP167 in cell lines were assessed by colony formation and MTT (proliferation) assays, Western blotting (apoptosis), and flow cytometry (cell cycle analysis). RESULTS: Elevated MELK expression was correlated with histological grading (n=6 data sets, p<0.05) and progression-free survival (HR 5.73, p<0.01) in OC patients and elevated MELK expression in other cancers with disease-free survival (n=3495, HR 1.071, p<0.001). Inhibition or depletion of MELK reduced cell proliferation and anchorage-dependent and -independent growth in various OC cell lines through a G2/M cell cycle arrest, eventually resulting in apoptosis. OTSSP167 retained its cytotoxicity in Cisplatin- and Paclitaxel-resistant IGROV1 and TYK-nu OC cells and sensitized OVCAR8 cells to Carboplatin but not Paclitaxel. CONCLUSION: MELK inhibition by OTSSP167 may thus present a strategy to treat patients with aggressive, progressive, and recurrent ovarian cancer.
The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.[Pubmed:24657156]
Biochem Biophys Res Commun. 2014 Apr 25;447(1):7-11.
Murine protein serine/threonine kinase 38 (MPK38), also known as maternal embryonic leucine zipper kinase (MELK), has been associated with various human cancers and plays an important role in the formation of cancer stem cells. OTSSP167, a MELK selective inhibitor, exhibits a strong in vitro activity, conferring an IC50 of 0.41nM and in vivo effect on various human cancer xenograft models. Here, we report the crystal structure of MPK38 (T167E), an active mutant, in complex with OTSSP167 and describe its detailed protein-inhibitor interactions. Comparison with the previous determined structure of MELK bound to the nanomolar inhibitors shows that OTSSP167 effectively fits into the active site, thus offering an opportunity for structure-based development and optimization of MELK inhibitors.
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.[Pubmed:27082996]
PLoS One. 2016 Apr 15;11(4):e0153518.
OTSSP167 was recently characterized as a potent inhibitor for maternal embryonic leucine zipper kinase (MELK) and is currently tested in Phase I clinical trials for solid tumors that have not responded to other treatment. Here we report that OTSSP167 abrogates the mitotic checkpoint at concentrations used to inhibit MELK. The abrogation is not recapitulated by RNAi mediated silencing of MELK in cells. Although OTSSP167 indeed inhibits MELK, it exhibits off-target activity against Aurora B kinase in vitro and in cells. Furthermore, OTSSP167 inhibits BUB1 and Haspin kinases, reducing phosphorylation at histones H2AT120 and H3T3 and causing mislocalization of Aurora B and associated chromosomal passenger complex from the centromere/kinetochore. The results suggest that OTSSP167 may have additional mechanisms of action for cancer cell killing and caution the use of OTSSP167 as a MELK specific kinase inhibitor in biochemical and cellular assays.